Using Mirabegron to Control Arrhythmia-1
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCedars-Sinai Medical Center
About this trial
To evaluate mirabegron's effect on ventricular arrhythmia control. The study will be conducted in ambulatory patients with ventricular tachycardia (VT), organic heart diseases, and an implantable cardioverter-defibrillator (ICD). The investigators will perform a pilot study involving 20 patients. Each will receive 50 mg of mirabegron. All will have neuECG recordings made before and 2 months after mirabegron. The data will be analyzed to test the proposed hypothesis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Provision of signed and dated informed consent form.
Age > 18 years old.
Documented VT on ICD.
with > 2 episodes of VT per month (on average) over the past 2 months.
Disqualifiers
Patients who are pacemaker-dependent because the pacing artifacts will complicate skin sympathetic nerve activity (SKNA) analysis.
Clinically unstable (for example, acute myocardial infarction, decompensated heart failure, undergoing cancer chemotherapy, and other acute illness requiring hospitalization)
Uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both)25
Active thyrotoxicosis
Trial design
Design model
Single group
Treatments tested in this trial
Mirabegron
DrugMirabegron is a beta-3 agonist approved by FDA to treat overactive bladder. Our preclinical studies showed that it is antiarrhythmic in the ventricles.
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: mirabegronExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
The primary endpoint is reduction of the burden of VT detected by ICD
The patients with ICD will record the VT burden. The investigators will use that number as the primary outcomes measure.
Time frame
3 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: